Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited (Nasdaq: ZURA) is a clinical-stage, multi-asset immunology company whose news flow centers on the development of novel antibodies for autoimmune and inflammatory diseases. Company announcements frequently highlight progress in its clinical pipeline, financial updates, and key corporate developments.
A major focus of Zura Bio’s news is tibulizumab (ZB-106), its lead investigational dual-pathway antibody targeting IL-17A and BAFF. Press releases describe the advancement of two Phase 2 trials: TibuSHIELD, a global randomized, double-blind, placebo-controlled study in adults with moderate to severe hidradenitis suppurativa, and TibuSURE, a global Phase 2 trial in adults with systemic sclerosis. Updates often cover trial initiation, enrollment status, study design details, and anticipated timelines for topline data readouts.
Investors and observers will also find quarterly and annual financial results reported by Zura Bio, including information on research and development spending, general and administrative expenses, net loss, and cash and cash equivalents. These releases typically include the company’s expectations about its cash runway and its ability to fund planned operations and clinical programs.
Additional news items include corporate and leadership changes, such as executive appointments, board transitions, and the establishment of advisory structures, as well as participation in healthcare and investor conferences where Zura Bio presents corporate overviews. The company also issues updates related to equity inducement grants and other compensation matters.
This news page aggregates these disclosures so readers can follow Zura Bio’s clinical milestones, financial condition, and organizational updates in one place. For those tracking ZURA, the feed offers an organized view of how the company’s immunology programs and corporate strategy are evolving over time.
Zura Bio (Nasdaq: ZURA) reported third quarter 2025 results and pipeline progress on November 13, 2025. The company reported $139.0 million in cash and cash equivalents as of September 30, 2025, which it expects will fund planned operations through 2027.
Zura continued advancement of two Phase 2 tibulizumab trials: TibuSHIELD (hidradenitis suppurativa) with topline data expected in Q3 2026, and TibuSURE (systemic sclerosis) with topline data expected in Q4 2026. Third-quarter 2025 operating items: R&D $11.9M (vs. $6.0M year-ago), G&A $7.6M (vs. $13.3M year-ago), and net loss $20.0M or $0.21 per share (vs. $22.9M, $0.26 per share).
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Cantor Fitzgerald Global Healthcare Conference. The company's leadership team will engage in a fireside chat on September 4, 2025, at 2:45 PM ET in New York.
The presentation will be accessible via live webcast through the Investors section of Zura Bio's website, with a replay available for at least 30 days. Additionally, the company will conduct one-on-one meetings with investors during the conference.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, reported Q2 2025 financial results and corporate updates. The company initiated TibuSHIELD, a Phase 2 study of tibulizumab for hidradenitis suppurativa, and continued progress on TibuSURE, another Phase 2 study for systemic sclerosis, with data readouts expected in Q3 2026 and Q4 2026 respectively.
Financial highlights include $154.5 million in cash and equivalents as of June 30, 2025, expected to fund operations through 2027. Q2 2025 net loss was $16.0 million ($0.17 per share), compared to $10.3 million in Q2 2024. R&D expenses increased to $8.7 million from $5.5 million year-over-year, while G&A expenses rose to $9.4 million from $6.2 million.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has granted inducement stock options to seven new employees. The company awarded options to purchase up to 890,950 Class A Ordinary Shares, including 672,000 options to newly appointed CFO Eric Hyllengren.
The grants, approved by the Compensation Committee and Board on July 15, 2025, were made outside the company's 2023 Equity Incentive Plan as employment inducements under Nasdaq Rule 5635(c)(4). The options vest 25% initially, followed by quarterly installments of 1/12th of remaining shares, subject to continued employment.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren will succeed Verender Badial, who will remain with the company as a non-executive employee through July 31, 2025, to ensure a smooth transition.
Hyllengren brings over 20 years of financial leadership experience in life sciences and biotechnology. He previously served as COO and CFO at Atara Biotherapeutics, where he managed strategic finance, capital markets, operational planning, and other key functions. Before that, he spent 15 years at Amgen in various roles including corporate finance, investor relations, and business development.
Badial, who joined Zura Bio in March 2023 during its business combination with JATT Acquisition Corporation, helped develop the company's financial systems and participated in capital-raising initiatives during his tenure.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's senior leadership will deliver a corporate overview on June 4, 2025, at 3:10 PM ET in New York. The presentation will be accessible via live webcast on Zura Bio's website, with a replay available for at least 30 days afterward. Additionally, the company will engage in one-on-one meetings with investors during the conference.
Zura Bio (NASDAQ: ZURA) reported its full year 2024 financial results, highlighting significant operational and financial achievements. The company completed a $112.5 million private placement in April 2024, ending the year with $176.5 million in cash and cash equivalents, providing runway through 2027.
Key developments include initiating the Phase 2 TibuSURE trial for systemic sclerosis and plans to launch a Phase 2 study for hidradenitis suppurativa in Q2 2025. Financial results show R&D expenses decreased to $24.4 million from $44.0 million in 2023, while G&A expenses increased to $30.8 million from $18.6 million. The company reported a net loss of $45.4 million ($0.60 per share) compared to $69.2 million ($2.09 per share) in 2023.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. The company's senior leadership team will engage in a fireside chat on Tuesday, March 11, 2025, at 1:40 p.m. ET in Miami, FL, where they will also host investor meetings.
The presentation will be accessible through a live webcast on the News & Events page of Zura Bio's website's Investors & Media section. For those unable to attend, a replay will be available and archived on the website for a minimum of 30 days after the event.